| 2.16 0.09 (4.35%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.65 | 1-year : | 2.96 |
| Resists | First : | 2.27 | Second : | 2.53 |
| Pivot price | 2.13  |
|||
| Supports | First : | 1.85 | Second : | 1.53 |
| MAs | MA(5) : | 2.11 |
MA(20) : | 2.19 |
| MA(100) : | 2.72 |
MA(250) : | 3.13 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 44 |
D(3) : | 43 |
| RSI | RSI(14): 44.6 |
|||
| 52-week | High : | 5.17 | Low : | 1.78 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GRCE ] has closed below upper band by 39.4%. Bollinger Bands are 76.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 64 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.19 - 2.21 | 2.21 - 2.22 |
| Low: | 1.99 - 2 | 2 - 2.02 |
| Close: | 2.14 - 2.16 | 2.16 - 2.18 |
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Fri, 14 Aug 2026
Grace Therapeutics (GRCE): ADAR1 group discloses 9.9% beneficial stake via warrants - Stock Titan
Fri, 14 Aug 2026
Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles - Stock Titan
Thu, 13 Aug 2026
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update - The Manila Times
Thu, 13 Aug 2026
Grace Therapeutics, Inc. Q1 2027: Net loss $(15.8)M, EPS $(0.91) — 10-Q Summary - TradingView
Thu, 13 Aug 2026
Grace Therapeutics (GRCE) books $13.5M R&D impairment, extends cash runway to 2028 - Stock Titan
Tue, 11 Aug 2026
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - stocktwits.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 23.5 (%) |
| Held by Institutions | 43 (%) |
| Shares Short | 1,630 (K) |
| Shares Short P.Month | 1,900 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.99 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10 % |
| Return on Equity (ttm) | -12 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -4.6 |
| PEG Ratio | 0 |
| Price to Book value | 0.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|